NASDAQ:MLNT - Melinta Therapeutics Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$4.45 +0.35 (+8.54 %)
(As of 09/19/2018 01:33 AM ET)
Previous Close$4.10
Today's Range$4.10 - $4.55
52-Week Range$3.95 - $18.20
Volume371,700 shs
Average Volume306,768 shs
Market Capitalization$238.04 million
P/E Ratio-0.20
Dividend YieldN/A
Melinta Therapeutics logoMelinta Therapeutics, Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes various anti-infectives for the treatment of bacterial infectious diseases in North America. It offers Baxdela, an antibiotic for the treatment of acute bacterial skin and skin structure infections (ABSSSI); Vabomere, a carbapenem used in treatment of gram-negative infections; Orbactiv, an antibiotic of the lipoglycopeptide class for the treatment of adult patients with ABSSSIs; and Minocin, a IV antibiotic of the tetracycline class with activity against gram-positive and gram-negative pathogens, as well as Solithromycin, a macrolide antibiotic for the treatment of CABP. The company also develops Baxdela that in a Phase III clinical trial for treating community-acquired bacterial pneumonia (CABP)); Fusidic Acid, which is in Phase III clinical trial for treating ABSSSIs; and radezolid, a melinta molecule that is in Phase II clinical trial for dermatological applications, as well as ESKAPE pathogen program, which is in preclinical stage targeting superbugs. Melinta Therapeutics, Inc. was formerly known as formerly Rib-X Pharmaceuticals, Inc. and changed its name to Melinta Therapeutics, Inc. in October 2013. The company was founded in 2000 and is headquartered in New Haven, Connecticut.

Receive MLNT News and Ratings via Email

Sign-up to receive the latest news and ratings for MLNT and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations


Debt-to-Equity Ratio0.41
Current Ratio1.97
Quick Ratio1.65


Trailing P/E Ratio-0.20
Forward P/E Ratio-1.12
P/E GrowthN/A

Sales & Book Value

Annual Sales$33.86 million
Price / Sales7.36
Cash FlowN/A
Price / CashN/A
Book Value$2.31 per share
Price / Book1.93


EPS (Most Recent Fiscal Year)($21.86)
Net Income$-58,910,000.00
Net Margins-348.51%
Return on Equity-67.60%
Return on Assets-35.09%


Outstanding Shares56,010,000
Market Cap$238.04 million

Melinta Therapeutics (NASDAQ:MLNT) Frequently Asked Questions

What is Melinta Therapeutics' stock symbol?

Melinta Therapeutics trades on the NASDAQ under the ticker symbol "MLNT."

How were Melinta Therapeutics' earnings last quarter?

Melinta Therapeutics, Inc. (NASDAQ:MLNT) released its quarterly earnings results on Tuesday, August, 7th. The biotechnology company reported ($1.38) EPS for the quarter, missing the consensus estimate of ($1.14) by $0.24. The biotechnology company had revenue of $12.02 million for the quarter, compared to analyst estimates of $12.06 million. Melinta Therapeutics had a negative return on equity of 67.60% and a negative net margin of 348.51%. View Melinta Therapeutics' Earnings History.

When is Melinta Therapeutics' next earnings date?

Melinta Therapeutics is scheduled to release their next quarterly earnings announcement on Thursday, November, 1st 2018. View Earnings Estimates for Melinta Therapeutics.

What price target have analysts set for MLNT?

7 Wall Street analysts have issued 1 year price targets for Melinta Therapeutics' stock. Their forecasts range from $2.00 to $15.00. On average, they anticipate Melinta Therapeutics' stock price to reach $10.80 in the next year. This suggests a possible upside of 142.7% from the stock's current price. View Analyst Price Targets for Melinta Therapeutics.

What is the consensus analysts' recommendation for Melinta Therapeutics?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Melinta Therapeutics in the last year. There are currently 1 hold rating and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Melinta Therapeutics.

What are Wall Street analysts saying about Melinta Therapeutics stock?

Here are some recent quotes from research analysts about Melinta Therapeutics stock:
  • 1. According to Zacks Investment Research, "Melinta Therapeutics, Inc. develops and commercializes novel antibiotics designed to provide new and better therapeutic solutions. Melinta's lead product is Baxdela, an antibiotic approved by the US FDA for use in the treatment of acute bacterial skin and skin structure infections (ABSSSI). Melinta also has an extensive pipeline of preclinical and clinical stage products that were developed internally or assumed under the 2017 acquisition of Cempra, Inc. This pipeline includes many important classes of antibiotics, each targeted at a different segment of the anti-infective market. Melinta is headquartered in New Haven, CT. " (9/13/2018)
  • 2. HC Wainwright analysts commented, "Valuation near-rock bottom: Market cap and EV below consideration paid for IDB acquisition just nine months ago. At closing, Melinta paid in cash and 3.3M shares (then worth about $55M). In addition, it agreed to two guaranteed payments of $25M in 2019 (recorded at fair value and accreted via non-cash interest expense). Thus, the total consideration for the infectious disease business was $270M, before any potential sales-based royalty payments (likely range: 5-15%; recorded at fair value of $14M and accreted via non-cash interest expense). By comparison, the current market capitalization and enterprise value of MLNT is $241M and $239M, respectively." (9/11/2018)
  • 3. Cantor Fitzgerald analysts commented, "We expect sales of key drugs (such as to exceed consensus expectations. Therefore, upwards earnings revisions should drive MLNT’s stock higher, in our view. Valuation Summary We use a blend of P/E and DCF analysis to arrive at our $15 PT. The Disclosure Section may be found on pages 3 – 5.Valuation We use a blend of P/E and DCF analysis to arrive at our $15 PT." (8/3/2018)

Who are some of Melinta Therapeutics' key competitors?

Who are Melinta Therapeutics' key executives?

Melinta Therapeutics' management team includes the folowing people:
  • Dr. Erin M. Duffy Ph.d., Chief Scientific Officer (Age 50)
  • Mr. Daniel Mark Wechsler, Pres, CEO & Director (Age 50)
  • Dr. Thomas A. Steitz Ph.D., Co-Founder
  • Dr. Peter B. Moore Ph.D., Co-Founder
  • Dr. William L. Jorgensen Ph.D., Co-Founder

Has Melinta Therapeutics been receiving favorable news coverage?

News headlines about MLNT stock have been trending somewhat positive recently, Accern reports. The research firm identifies positive and negative news coverage by reviewing more than twenty million news and blog sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Melinta Therapeutics earned a media and rumor sentiment score of 0.18 on Accern's scale. They also gave media coverage about the biotechnology company an impact score of 46.57 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock's share price in the next several days. View Recent Headlines for Melinta Therapeutics.

Who are Melinta Therapeutics' major shareholders?

Melinta Therapeutics' stock is owned by many different of retail and institutional investors. Top institutional shareholders include FMR LLC (10.07%), BlackRock Inc. (5.29%), First Manhattan Co. (3.83%), Millennium Management LLC (3.70%), Dimensional Fund Advisors LP (1.73%) and Granahan Investment Management Inc. MA (0.97%). Company insiders that own Melinta Therapeutics stock include David N Gill, Dov A Md Goldstein, Paul Estrem, Sue Cammarata and Vatera Healthcare Partners Llc. View Institutional Ownership Trends for Melinta Therapeutics.

Which major investors are selling Melinta Therapeutics stock?

MLNT stock was sold by a variety of institutional investors in the last quarter, including Pennsylvania Trust Co. View Insider Buying and Selling for Melinta Therapeutics.

Which major investors are buying Melinta Therapeutics stock?

MLNT stock was purchased by a variety of institutional investors in the last quarter, including FMR LLC, First Manhattan Co., BlackRock Inc., Millennium Management LLC, Granahan Investment Management Inc. MA, Schwab Charles Investment Management Inc., Laurion Capital Management LP and Northern Trust Corp. Company insiders that have bought Melinta Therapeutics stock in the last two years include David N Gill, Paul Estrem, Sue Cammarata and Vatera Healthcare Partners Llc. View Insider Buying and Selling for Melinta Therapeutics.

How do I buy shares of Melinta Therapeutics?

Shares of MLNT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Melinta Therapeutics' stock price today?

One share of MLNT stock can currently be purchased for approximately $4.45.

How big of a company is Melinta Therapeutics?

Melinta Therapeutics has a market capitalization of $238.04 million and generates $33.86 million in revenue each year. The biotechnology company earns $-58,910,000.00 in net income (profit) each year or ($21.86) on an earnings per share basis. Melinta Therapeutics employs 300 workers across the globe.

How can I contact Melinta Therapeutics?

Melinta Therapeutics' mailing address is 300 GEORGE STREET SUITE 301, NEW HAVEN CT, 06511. The biotechnology company can be reached via phone at 908-617-1309 or via email at [email protected]

MarketBeat Community Rating for Melinta Therapeutics (NASDAQ MLNT)

Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  454 (Vote Outperform)
Underperform Votes:  310 (Vote Underperform)
Total Votes:  764
MarketBeat's community ratings are surveys of what our community members think about Melinta Therapeutics and other stocks. Vote "Outperform" if you believe MLNT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MLNT will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 9/19/2018 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.

Yahoo Gemini Pixel